ALT · Categories · Earnings
ALT - Earnings announcements
Altimmune Inc. (ALT) earnings announcements - real-time wire coverage filtered to Earnings only.
Recent Earnings for ALT
- Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026GAITHERSBURG, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its first quarter 2026 financial results on Wednesday, May 13, 2026. Altimmune management will host a conference call at 8:30 a.m. ET on May 13 to discuss the financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive dial-in numbers and a unique PIN. A replay will be available on the
- Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its fourth quarter 2025 financial results on Thursday, March 5, 2026. Altimmune management will host a conference call at 8:30 a.m. ET on March 5 to discuss the financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive dial-in numbers and a unique PIN. A replay will be available on t
- Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH TrialImprovements observed in key non-invasive markers of fibrosis across treatment arms versus placebo, with continued reductions from 24-week timepoint Additional weight loss from 24 to 48 weeks with 1.8 mg dose, without plateauing Favorable tolerability profile of pemvidutide preserved at 48 weeks, reinforced by low treatment-related discontinuation rate End-of-Phase 2 meeting with FDA supports advancing to registrational Phase 3 trial in MASH patients with moderate to advanced liver fibrosis Conference call to be held today at 8:00 a.m. ET GAITHERSBURG, Md., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing thera
- Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025GAITHERSBURG, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it will report its third quarter 2025 financial results on Thursday, November 6, 2025. Altimmune management will host a conference call at 8:30 a.m. ET on November 6 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to
- Altimmune Announces Second Quarter 2025 Financial Results and Business UpdatePositive data from the IMPACT Phase 2b trial reinforces the potential for pemvidutide to be a highly differentiated MASH therapy Pemvidutide is the first product candidate to achieve statistically significant MASH resolution and weight loss at 24 weeks New data from the IMPACT trial demonstrates potentially class-leading improvements in corrected T1 (cT1), an important marker of liver inflammation and fibrosis End-of-Phase 2 Meeting with FDA expected in Q4 2025 Cash, cash equivalents and short-term investments of $183.1 million as of June 30, 2025 Webcast to be held today, August 12, 2025, at 8:30 a.m. ET GAITHERSBURG, Md., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:A
- Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025GAITHERSBURG, Md., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2025 financial results on Tuesday, August 12, 2025. Altimmune management will host a conference call at 8:30 am E.T. on August 12 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor R
- Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASHFirst product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis in up to 59.1% of participants in an ITT analysis Fibrosis improvement without worsening of MASH in up to 34.5% of participants in an ITT analysis Supplemental AI-based analysis demonstrated statistically significant reductions in liver fibrosis at 24 weeks Weight loss of up to 6.2% at 24 weeks with no plateauing Potentially best-in-class tolerability, with less than 1% treatment discontinuations due to adverse events in pemvidutide-treated participants Conference call to be held on June 2
- Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26GAITHERSBURG, Md., June 25, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, will host an investor webcast on Thursday, June 26, 2025 at 8:30 am E.T. to present topline 24 week data from its IMPACT Phase 2b trial evaluating pemvidutide in the treatment of patients with metabolic dysfunction-associated steatohepatitis (MASH). Conference Call InformationThe Company will host a conference call and webcast at 8:30 am E.T. on June 26, 2025. The call will include remarks from Altimmune management and Dr. Mazen Noureddin, Professor of Medicine at the H
- Altimmune Announces First Quarter 2025 Financial Results and Business UpdateTop-line data from IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) expected in Q2 2025 Phase 2 trials in Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD), expected to initiate in Q2 and Q3 2025, respectively Cash, cash equivalents and short-term investments of $150 million as of March 31, 2025 $100 million credit facility secured with Hercules Capital, adding balance sheet strength and financial flexibility to support continued development of pemvidutide Webcast to be held today, May 13, 2025, at 8:30 a.m. ET GAITHERSBURG, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceuti
- Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025GAITHERSBURG, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2025 financial results on Tuesday, May 13, 2025. Altimmune management will host a conference call at 8:30 am E.T. on May 13 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations
- Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business UpdateTop-line data from Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) to be reported in Q2 2025 Investigational New Drug (IND) applications in two additional indications have received FDA clearance, with Phase 2 trials to commence mid-2025 Company to hold virtual R&D Day on March 13, 2025. Program will include KOL presentations on pemvidutide development in obesity, MASH and additional indications Two pharmaceutical industry veterans added to Company Board of Directors Cash, cash equivalents and short-term investments of $131.9 million on December 31, 2024 Webcast to be held today, February 27, 2025, at 8:30 a.m. ET GAITHERSBURG, Md., Feb.
- Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025GAITHERSBURG, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025. Altimmune management will host a conference call at 8:30 am E.T. on February 27 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on
- Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business UpdateEnrollment completed in Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH); top-line efficacy data expected in Q2 2025 Successful completion of the obesity End-of-Phase 2 meeting with the FDA Company plans to submit Investigational New Drug (IND) applications for pemvidutide in up to three additional indications beginning Q4 2024 Cash, cash equivalents and short-term investments of $139.4 million on September 30, 2024 Webcast to be held today, November 12, 2024, at 8:30 a.m. ET GAITHERSBURG, Md., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced financial results for
- Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024GAITHERSBURG, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2024 financial results on Tuesday, November 12, 2024 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on November 12 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay wi
- Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business UpdateRecent presentations at major medical meetings provide further support for the differentiated profile of pemvidutide in obesity and metabolic dysfunction-associated steatohepatitis (MASH) Enrollment progressing in Phase 2b IMPACT trial of pemvidutide in MASH with topline data expected in Q1 2025 Cash, cash equivalents and short-term investments of $164.9 million on June 30, 2024 Webcast to be held today, August 8, 2024, at 8:30 am ET GAITHERSBURG, Md., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2024, and provided a business update. "During the second
- Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024GAITHERSBURG, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on August 8 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will b
- Altimmune Announces First Quarter 2024 Financial Results and Provides a Business UpdateEnrollment ongoing in IMPACT Phase 2b trial of pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH), with top line results expected in Q1 2025 Cash, cash equivalents and short-term investments of $182.1 million at March 31, 2024 Webcast to be held today, May 9, 2024, at 8:30 am ET GAITHERSBURG, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2024, and provided a business update. "As the obesity therapeutics space evolves, increasing attention is being placed on agents that are able to drive weight loss while addressing the qua
- Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024GAITHERSBURG, Md., May 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on May 9 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be availa
- Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial ResultsBody composition study showed lean mass preservation, with only 25.5% of weight loss derived from lean mass Enrollment ongoing in IMPACT Phase 2b trial of pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH), with topline 24-week data expected Q1 2025 Preclinical study results showed a direct anti-fibrotic effect of pemvidutide in anon-steatotic model of liver fibrosis Cash, cash equivalents and short-term investments of $198.0 million at December 31, 2023 Webcast to be held today, March 27, 2024, at 8:30 am ET GAITHERSBURG, Md., March 27, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biophar
- Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024GAITHERSBURG, Md., March 20, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2023 financial results on Wednesday, March 27, 2024 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on March 27 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call,
- Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of PemvidutideAchieved mean weight loss of 15.6% on 2.4 mg dose of pemvidutide at Week 48, with weight loss continuing at the end of treatmentOver 30% of subjects achieved 20% or more weight loss on 2.4 mg dose at 48 weeks Robust reductions in BMI and serum lipids and improvements in blood pressure without imbalances in cardiac events, arrhythmias or clinically meaningful increases in heart rate Altimmune to host conference call tomorrow at 8:30 am EST GAITHERSBURG, Md., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company (the "Company"), today announced topline results from its 48-week MOMENTUM Phase 2 obesity trial of pemvidutide. The trial enro
- Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business UpdateTop-line 48-week results from the MOMENTUM Phase 2 obesity trial expected Q4 2023 Pemvidutide granted Fast Track designation for the treatment of non-alcoholic steatohepatitis (NASH) Top-line results from the Phase 2 trial of HepTcell™ in chronic hepatitis B (CHB) expected Q1 2024 Webcast to be held today, November 7, 2023, at 8:30 am EST GAITHERSBURG, Md., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three months ended September 30, 2023, and provided a business update. "The next few months will be important as we receive the data from our 48-week MOMENTUM trial of pemvidutide in
- Altimmune to Report Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023GAITHERSBURG, Md., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2023 financial results on Tuesday, November 7, 2023 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on November 7 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a rep
- Altimmune Announces Second Quarter 2023 Financial Results and Provides a Business UpdateTop-line 48-week results from the MOMENTUM Phase 2 obesity trial expected Q4 2023 Commenced enrollment in IMPACT Phase 2b trial of pemvidutide in non-alcoholic steatohepatitis (NASH) Top-line results from the Phase 2 trial of HepTcell™ in chronic hepatitis B (CHB) expected Q1 2024 Webcast to be held today, August 10, 2023, at 8:30 am EDT GAITHERSBURG, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three months ended June 30, 2023, and provided a business update. "We are pleased to have commenced enrollment in our IMPACT Phase 2b biopsy-driven trial of pemvidutide in NASH," said
- Altimmune to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023GAITHERSBURG, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2023 financial results on Thursday, August 10, 2023 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on August 10 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will
- Altimmune Announces First Quarter 2023 Financial Results and Provides a Business UpdateInitiation of the IMPACT Phase 2b trial of pemvidutide in non-alcoholic steatohepatitis (NASH) expected mid-2023 Top-line 48-week results from the MOMENTUM Phase 2 obesity trial expected Q4 2023 Top-line results from the Phase 2 trial of HepTcell™ in chronic hepatitis B (CHB) expected Q1 2024 Webcast to be held today, May 11, 2023, at 8:30 am EDT GAITHERSBURG, Md., May 11, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three months ended March 31, 2023, and provided a business update. "We are on course for mid-year initiation of IMPACT, our Phase 2b biopsy trial of pemvidutide in subjects wit
- Altimmune to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023GAITHERSBURG, Md., May 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2023 financial results on Thursday, May 11, 2023 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on May 11 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be avai
- Altimmune Announces Positive Results from Week 24 Interim Analysis of Pemvidutide MOMENTUM Phase 2 Obesity Trial and 12-Week Phase 1b Type 2 Diabetes Safety TrialMOMENTUM Phase 2 Obesity Trial (Week 24 Interim Analysis of 160 Subjects) Mean weight loss of 10.7% (placebo-adjusted 9.7%) at 2.4 mg dose at Week 24Mean weight loss of 11.9% (placebo-adjusted 11.1%) in subjects weighing 115 kg or less at baseline at 2.4 mg dose at Week 24Approximately 50% of subjects achieved 10% or more weight loss and approximately 20% of subjects achieved 15% or more weight loss at the 1.8 mg and 2.4 mg doses at Week 24Robust reductions in waist circumference, serum lipids and blood pressure without meaningful increases in heart rateRates of gastrointestinal (GI) adverse events (AEs) similar to earlier pemvidutide trials Phase 1b Type 2 Diabetes Safety Trial (Week 12 E
- Altimmune Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business UpdateInterim 24-week readout from MOMENTUM Phase 2 obesity trial expected March 2023 Initiation of Phase 2b non-alcoholic steatohepatitis (NASH) trial expected mid-2023 Webcast to be held today, February 28, 2023, at 8:30 am ET GAITHERSBURG, Md., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update. "The next twelve-months is an important period for potential value-creating data readouts and the clinical development of pemvidutide, our GLP-1/glucagon dual-receptor agonist which is being developed for the treatme
- Altimmune to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023GAITHERSBURG, Md., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on February 28 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after th
- Altimmune Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)Greater than 75% relative reduction in liver fat content achieved at the 1.8 mg and 2.4 mg doses at 24 weeksSignificant reductions in serum alanine aminotransferase (ALT) and corrected T1 (cT1) observed, both established markers of liver inflammationMean weight loss of 7.2% (placebo adjusted 6.0%) in subjects without diabetes at the 1.8 mg doseGlycemic control maintained with trends toward improvements in fasting glucose and HbA1c in subjects with diabetesMeaningful reductions in blood pressure with minimal increases in heart rateAltimmune to host conference call today at 8:30 am ET GAITHERSBURG, Md., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-sta
- Altimmune Announces Third Quarter 2022 Financial Results and Provides a Business UpdateTopline 24-week data from Phase 1b trial in subjects with non-alcoholic fatty liver disease (NAFLD) expected mid-December 2022 Interim 24-week readout from MOMENTUM Phase 2 obesity trial expected Q1 2023 GAITHERSBURG, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and nine months ended September 30, 2022, and provided a business update. "We continue on course in our advancement of pemvidutide for two important clinical indications, obesity and non-alcoholic steatohepatitis (NASH), and look forward to data readouts from our NAFLD trial extension in mid-December 2022 and from
- Altimmune to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10GAITHERSBURG, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2022 financial results on Thursday, November 10, 2022 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on November 10 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay w
- Altimmune Announces Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of Pemvidutide in Subjects with NAFLDAll 3 pemvidutide dosing groups (1.2 mg, 1.8 mg, 2.4 mg) achieved the primary endpoint of relative and absolute reductions in liver fat, with a 68.5% relative reduction in liver fat content in subjects receiving 1.8 mg dose at 12 weeks of treatmentMean weight loss of 4.9% (placebo-adjusted 4.7%) in subjects without diabetes receiving 1.8 mg dose at 12 weeks of treatmentAltimmune to host conference call today at 8:30 am ET GAITHERSBURG, Md., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced positive topline results from its 12-week Phase 1b study of pemvidutide1 in subjects with non-alcoholic fatty liver disease (NA
- Altimmune Announces Second Quarter 2022 Financial Results and Provides a Business UpdateGAITHERSBURG, Md., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and six months ended June 30, 2022, and provided a business update. "We continue to advance the development of pemvidutide, our GLP-1/glucagon dual receptor agonist, and look forward to reporting important readouts from our ongoing clinical trials during the coming months," said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. "We expect to announce top line data from our 12-week trial in subjects with obesity/overweight and NAFLD in mid-September 2022, followed by 24-week data from an exte
- Altimmune to Report Second Quarter 2022 Financial Results and Provide Business Update on August 11GAITHERSBURG, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2022 financial results on Thursday, August 11, 2022 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on August 11 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will
- Altimmune Announces First Quarter 2022 Financial Results and Provides a Corporate UpdateGAITHERSBURG, Md., May 12, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three months ended March 31, 2022 and provided a corporate update. "We continue to advance the development of pemvidutide, our GLP-1/Glucagon dual receptor agonist and look forward to reporting both weight loss and liver fat reduction data from multiple ongoing clinical trials later this year," said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. "Based on a greater than 10% weight loss after only 12 weeks of treatment, we believe that pemvidutide has the potential to deliver weight loss comparable
- Altimmune to Report First Quarter 2022 Financial Results and Provide Business Update on May 12GAITHERSBURG, Md., May 05, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2022 financial results on Thursday, May 12, 2022 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on May 12 to discuss financial results and provide a business update. Conference Call Information: Date:Thursday, May 12Time:8:30 am Eastern TimeDomestic Dial-in:(800) 225-9448International Dial-in:(203) 518-9708Conference ID:ALTQ122Webcast:https://edge.media-server.com/mmc/p/j5i9f735 About Altimmune Altimmune is a clinical-stage biopharmaceutical company focused
- Altimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate UpdateData readouts from multiple clinical trials expected during the next 6 to 12 months Strong cash position of $190.3 million as of December 31, 2021 GAITHERSBURG, Md., March 15, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update. "We expect the next 12 months to be a period of intense execution with value-creating data readouts from multiple clinical trials. We are extremely pleased with the progress of our pemvidutide (ALT-801) program as we showed double-digit weight loss after
- Altimmune to Report Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022GAITHERSBURG, Md., March 08, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2021 financial results on Tuesday, March 15, 2022. Altimmune management will host a conference call at 8:30 am E.T. on March 15 to discuss financial results and provide a business update. Conference Call Information: Date:Time:Domestic Dial-in:International Dial-in:Conference ID:Webcast:Tuesday, March 158:30 am Eastern Time(844) 615-6509(918) 922-31484557398https://edge.media-server.com/mmc/p/5www3cgz About Altimmune Altimmune is a clinical-stage biopharmaceutical company focused on the deve
- Altimmune Announces Third Quarter 2021 Financial Results and Provides a Corporate UpdateExploratory MRI-PDFF analysis of subjects with hepatic steatosis in recently completed Phase 1 study of pemvidutide shows reduction of liver fat to undetectable levels after 6 weeks of treatment Approximately $200 Million in cash and short-term investments to advance pipeline GAITHERSBURG, Md., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three- and nine-months ending September 30, 2021 and provided a corporate update. "The third quarter was a momentous time for our pemvidutide (ALT-801) program, as we delivered on positive topline data for the 12-week Phase 1 trial
- Altimmune to Announce Third Quarter 2021 Financial Results on November 10, 2021GAITHERSBURG, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2021 financial results on Wednesday, November 10, 2021. Altimmune management will host a conference call for investors beginning at 8:30 am E.T. to discuss the third quarter 2021 financial results and provide a business update. Conference Call Information: Date:Wednesday, November 10Time:8:30 am Eastern TimeDomestic Dial-in:(844) 615-6509International Dial-in:(918) 922-3148Conference ID:5783655Webcast:https://edge.media-server.com/mmc/p/zgrrmubx About AltimmuneAltimmune is a clinical stage biopharmaceutical co
- Altimmune to Host Key Opinion Leader Call with Dr. Stephen Harrison on Pemvidutide Phase 1 Clinical Trial Results on September 30, 2021GAITHERSBURG, Md., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will host a Key Opinion Leader (KOL) call on its 12-week Phase 1 clinical trial of pemvidutide (proposed INN, formerly known as ALT-801) in overweight and obese subjects on Thursday, September 30, 2021 at 9:00 am EST. The call will feature a discussion with Stephen A. Harrison, MD (Pinnacle Clinical Research), a leading expert in the field of non-alcoholic steatohepatitis (NASH) and liver diseases, on the safety profile and weight loss data generated from Altimmune's Phase 1 clinical trial. Dr. Harrison will be available to answer question
- Altimmune Announces Positive Results From 12-week Phase 1 Clinical Trial of ALT-801 (Pemvidutide) in Overweight and Obese VolunteersMean weight loss of 10.3% achieved in subjects receiving 1.8 mg dosePemvidutide was well-tolerated without the need for dose titration No discontinuations due to treatment-emergent adverse eventsNASH IND has cleared FDA review; 12-week NAFLD study to begin in the near futureAltimmune to host a conference call today at 8:30 am EST GAITHERSBURG, Md., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced positive results from a 12-week, Phase 1 trial of pemvidutide (proposed INN, formerly known as ALT-801), an investigational glucagon-like peptide-1 (GLP-1)/glucagon dual receptor agonist. The Phase 1 study was a firs
- Altimmune to Announce 12-Week Data From ALT-801 Phase 1 Trial on September 28, 2021GAITHERSBURG, Md., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report the results from its 12-week Phase 1 clinical trial of ALT-801 in overweight and obese subjects in a pre-market press release and webcast to be held on Tuesday, September 28, 2021. Altimmune management will host a conference call and webcast with a slide presentation beginning at 8:30 am E.T. Following the conclusion of the call, the webcast will be available for replay on the Investor Relations page of the Company's website at www.altimmune.com. The company has used, and intends to continue to use, the IR portion of its we
- Altimmune Announces Second Quarter 2021 Financial Results and Provides a Corporate Update12-week Data Readout from ALT-801 Phase 1 Clinical Trial Expected in September Approximately $218 Million in Cash and Short-Term Investments to Advance Obesity and Liver Disease Pipeline GAITHERSBURG, Md., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three- and six-months ending June 30, 2021 and provided a corporate update. "Following data readouts in Q2, Altimmune has focused its efforts on our NASH and emerging obesity pipeline with the encouraging interim data from the ALT-801 Phase 1 trial reinforcing the potential of these programs," remarked Vipin K. Garg, Ph.D., Presid
- Altimmune to Announce Second Quarter 2021 Financial Results on August 11, 2021GAITHERSBURG, Md., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2021 financial results on Wednesday, August 11, 2021. Altimmune management will host a conference call for investors beginning at 8:30 am E.T. to discuss the second quarter 2021 financial results and provide a business update. Conference Call Information: Date:Wednesday, August 11Time: 8:30 am Eastern TimeDomestic Dial-in: (844) 615-6509International Dial-in:(918) 922-3148Conference ID: 9484516Webcast:https://edge.media-server.com/mmc/p/ne5cqqtf About AltimmuneAltimmune is a clinical stage biopharmaceutical c